Evidence map›Paper›PMID 29521009›Full record

ArticleBJU international2018

Obese patients with castration-resistant prostate cancer may be at a lower risk of all-cause mortality: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database.

Adriana C Vidal, Lauren E Howard, Amanda de Hoedt, Christopher J Kane, Martha K Terris, William J Aronson, Matthew R Cooperberg, Christopher L Amling, Stephen J Freedland

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in BJU international, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Review
  5. Article
  6. Observational
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Adriana C VidalDivision of Urology, Department of Surgery, Cedars Sinai Medical Center, Los Angeles, CA, USA.ORCID 0000-0002-3240-6668
Lauren E HowardUrology Section, VA Medical Center, Durham, NC, USA.
Amanda de HoedtUrology Section, VA Medical Center, Durham, NC, USA.ORCID 0000-0002-3899-7702
Christopher J KaneUrology Department, University of California San Diego Health System, San Diego, CA, USA.
Martha K TerrisSection of Urology, VA Medical Center Augusta, Augusta, GA, USA.
William J AronsonUrology Section, Department of Surgery, Veterans Affairs (VA) Greater Los Angeles Healthcare System, Los Angeles, CA, USA.
Matthew R CooperbergDepartment of Urology, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA, USA.
Christopher L AmlingDivision of Urology, Oregon Health Sciences University, Portland, OR, USA.ORCID 0000-0002-6559-3340
Stephen J FreedlandDivision of Urology, Department of Surgery, Cedars Sinai Medical Center, Los Angeles, CA, USA.

Funding

UCLA SPORE IN PROSTATE CANCERP50CA092131 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI FREEMAN, MICHAEL R · 2002 to 2023
$42.6M
IGF-I: A Nutrition-Regulated Target in Prostate CancerR01CA100938 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI COHEN, PINCHAS · 2003 to 2007
$1.7M
Midcareer Investigator AwardK24CA160653 · NCI · DUKE UNIVERSITY · PI FREEDLAND, STEPHEN JAY · 2012 to 2016
$877k
NCI NIH HHS K24 CA160653NCI NIH HHS P50 CA092131NCI NIH HHS R01 CA100938
6 · The paper itself

Abstract

objectiveTo assess whether obesity is associated with progression to metastasis, prostate cancer-specific mortality (PCSM), and all-cause mortality (ACM), in patients with non-metastatic castration-resistant prostate cancer (non-mCRPC). At the population level, obesity is associated with prostate cancer mortality; however, some studies have found that higher body mass index (BMI) is associated with better long-term prostate cancer outcomes amongst men with mCRPC. PATIENTS AND

methodsWe identified 1 192 patients with non-mCRPC from the Shared Equal Access Regional Cancer Hospital (SEARCH) database. BMI was calculated from height and weight abstracted from the medical records at the time closest to but prior to CRPC diagnosis and categorised as underweight (<21 kg/m

resultsOverall, 51 (4%) men were underweight, 239 (25%) were normal weight, 464 (39%) were overweight, and 438 (37%) were obese. In adjusted analysis, higher BMI was significantly associated with reduced ACM (hazard ratio [HR] 0.98, P = 0.012) but not PCSM (HR 1.00, P = 0.737) or metastases (HR 0.99, P = 0.225). Likewise, when BMI was treated as a categorical variable in adjusted models, obesity was not associated with PCSM (HR 1.11, P = 0.436) or metastases (HR 1.06, P = 0.647), but was associated with decreased ACM (HR 0.79, P = 0.016) compared to normal weight. No data were available on treatments received after CRPC diagnosis.

conclusionsAmongst patients with non-mCRPC obesity was associated with better overall survival. Although this result mirrors evidence from men with mCRPC, obesity was not associated with prostate cancer outcomes. Larger studies are needed to confirm these findings.

Indexed as

AgedAged, 80 and overCause of DeathHumansMaleNeoplasm MetastasisObesityPrognosisProstatectomyProstatic Neoplasms, Castration-ResistantRisk FactorsUnited Statescastration-resistant prostate cancerobesity#PCSM#ProstateCancer

Identifiers

PMID29521009
PMCPMC5997525

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.